In addition, crizotinib appears to be effective in the treatment of EGFR-mutated NSCLCs consisting of MET amplifications, which contribute acquired resistance in about 10% of EGFR-mutated NSCLC cases [60,61,62]. Here, MET is linked to non-small cell lung carcinoma.